Revealing the Mind: The Promise of Psychedelics

"Revealing the Mind: The Promise of Psychedelics" is a 2019 World Science Festival panel, moderated by journalist Emily Senay, bringing a psychiatrist, a consciousness researcher, a developmental psychologist, and an anthropologist together to discuss what psychedelics reveal about the mind. It moves from the history of psychedelic science through the neuroscience of ego dissolution to the clinical case for psilocybin therapy, closing with each panelist's outlook, and stresses throughout that context, often called set and setting, shapes whether these experiences help or harm.

A field shut down for thirty years, and four experts who revived it

Humans have used psychedelic plants and fungi for millennia, the video cites 9,000-year-old cave paintings of mushroom rituals, but the modern story starts in 1943, when chemist Albert Hofmann accidentally absorbed LSD at Sandoz Laboratories and later took a deliberate dose (now marked as Bicycle Day). Sandoz gave LSD free to researchers worldwide through the 1950s and 60s, until Timothy Leary's ouster from Harvard and CIA interest pushed the drugs into the counterculture, and Nixon's 1970 Controlled Substances Act classified LSD and psilocybin as Schedule I, stalling research for roughly three decades. Reviving the field are NYU psychiatrist Stephen Ross, Sussex neuroscientist Anil Seth, Berkeley psychologist and philosopher Alison Gopnik, and McGill anthropologist Eduardo Kohn. Ross defines classic psychedelics as drugs acting mainly through the serotonin 2A receptor, grouping LSD, psilocybin, and DMT (in ayahuasca) together. Ketamine, blocking the NMDA receptor, is already approved for treatment-resistant depression; MDMA has some addictive potential and FDA breakthrough status for PTSD.

Perception, the self, and the psychedelic brain

Seth reframes perception as a construction the brain builds from sensory input and prior expectation. "I like to think about perception as a kind of controlled hallucination," he says. The self, including body ownership and continuity over time, is itself a perception, and ego dissolution reflects a rearrangement of the processes that assemble it. With Imperial College London, his team found psilocybin and LSD increase randomness in brain activity, and that resting-state networks, including the default mode network, reorganize.

Children, the Amazon, and openness without drugs

Gopnik links this to development: young brains favor short-range connections and are built for exploration over efficiency; pruning across childhood trades flexibility for competence. Psychedelics, she suggests, may temporarily reopen that plastic state, alongside routes like meditation. Kohn describes how the community he works with uses ayahuasca, dreaming, and attention to the forest as technologies for stepping outside everyday thought and connecting with the "mind of the forest." A clip shows an elder preparing ayahuasca and a ceremony; Kohn stresses this is a deliberate, ritualized practice for healing or communal problems, not recreation.

Mystical experience and the philosophical questions it raises

Ross describes an NYU study giving high-dose psilocybin to religious professionals, tracing the idea to Walter Pahnke's 1962 "Marsh Chapel" experiment at Harvard, where divinity students given psilocybin reported full mystical experiences far more often than a niacin control group. In Ross's cancer trials, this mystical-type experience's intensity correlated with psilocybin's anti-anxiety and antidepressant effects. Gopnik raises a puzzle: these experiences often carry what William James called a "noetic" quality, a felt sense of truth. Kohn adds that the elders he works with describe the forest as an ongoing "emergent mind" under threat. "The call from the Amazon is to live psychedelically," he says, framing this as the community's worldview, not a scientific claim.

From lab to clinic: the case for psilocybin therapy

Ross entered the field in 2006, learning how much psychedelic research had already been done between the 1950s and early 1970s. The strongest evidence comes from three randomized controlled trials (UCLA, Johns Hopkins, NYU, 92 participants total) testing a single high dose of psilocybin for cancer-related anxiety and depression. Ross reports 80 percent no longer met criteria for depression one day after dosing, effects persisting at seven weeks and eight months for many, versus 20 to 40 percent in placebo groups. Participants Octavian Mihai and Dinah Bazer describe on stage how a single session reduced fear tied to their diagnoses. Ross also outlines trials for major depression, alcoholism, addiction, and anorexia.

Risks, "freelancing," and where the science is headed

Ross flags psychosis risk, especially for people already prone to it, screens out significant heart problems, and warns ayahuasca, an MAO inhibitor, combined with serotonergic antidepressants can cause serotonin syndrome. Kohn and Gopnik raise ayahuasca tourism and unsupervised microdosing as use outside the screening and integration that traditional and clinical settings provide. Several panelists return to set and setting: impact depends heavily on context and a trained guide, and as Seth puts it, freelancing is probably not the best approach. Ross predicts psilocybin and MDMA, given through licensed clinics, could become available within about five years, starting with cancer-related distress, though he frames this as his own projection, not a guarantee.

Key takeaways

• ●Classic psychedelics (LSD, psilocybin, DMT) act mainly on the serotonin 2A receptor and are not considered addictive by the panel's psychiatrist.
• ●Ketamine is already approved for treatment-resistant depression and MDMA holds FDA breakthrough status for PTSD, both distinct from classic psychedelics.
• ●Brain imaging shows psilocybin and LSD increase randomness in brain activity and reorganize the default mode network, changes linked to ego dissolution.
• ●Three combined randomized trials (92 participants) found a single high dose of psilocybin rapidly reduced cancer-related depression and anxiety, some effects lasting seven weeks to eight months.
• ●The intensity of the mystical-type experience correlates with psilocybin's therapeutic effects, a link traced to a 1962 Harvard study on religious professionals.
• ●Amazonian communities use ayahuasca as one of several ritualized technologies for healing and communal problem-solving, not recreation.
• ●The panel warns against unsupervised "freelancing," citing psychosis risk, a serious ayahuasca-antidepressant interaction, and the need for screening and integration.